<p>MIRA Pharmaceuticals, Inc.（納斯達克代碼：MIRA - 獲取免費報告）在週三的交易中上漲了 2.1%。該公司的股價最高達到 1.55 美元，最後交易價格為 1.48 美元。在交易中大約有 418,018 股易手，比平均每日交易量 185,498 股增加了 125%。該股票之前的收盤價為 1.45 美元。</p>
<p>獲取 <strong>MIRA Pharmaceuticals</strong> 的提醒：</p>
<h2>華爾街分析師預測增長</h2>
<p>多家券商最近對 MIRA 進行了評估。華爾街 Zen 在 11 月 22 日的報告中將 MIRA Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。Weiss Ratings 在 12 月 10 日的研究報告中重申了對 MIRA Pharmaceuticals 的 “賣出（d-）” 評級。根據 MarketBeat 的數據顯示，一位分析師對該股票給予了賣出評級，MIRA Pharmaceuticals 的共識評級為 “賣出”。</p>
<p><strong>查看我們關於 MIRA Pharmaceuticals 的最新報告</strong></p>
<h2>MIRA Pharmaceuticals 股票上漲 2.1%</h2>
<p>該股票的市值為 6198 萬美元，市盈率為-0.97，貝塔值為 1.79。該公司的 50 日簡單移動平均線為 1.47 美元，200 日簡單移動平均線為 1.42 美元。</p>
<p>MIRA Pharmaceuticals（納斯達克代碼：MIRA - 獲取免費報告）最近在 11 月 13 日發佈了季度財報。該公司報告每股收益（EPS）為-1.18 美元，低於共識預期的-0.11 美元，差距為-1.07 美元。分析師預計 MIRA Pharmaceuticals, Inc.在當前財政年度的每股收益將為-0.6 美元。</p>
<h2>機構投資者對 MIRA Pharmaceuticals 的看法</h2>
<p>幾家機構投資者最近對 MIRA 的持倉進行了調整。第一美洲銀行在第三季度將其在 MIRA Pharmaceuticals 的持倉增加了 150.0%。第一美洲銀行現在擁有 50,000 股該公司的股票，價值 68,000 美元，此前在上個季度又購買了 30,000 股。Two Sigma Investments LP 在第三季度將其在 MIRA Pharmaceuticals 的股份增加了 129.8%。Two Sigma Investments LP 現在擁有 45,703 股該公司的股票，價值 62,000 美元，此前在此期間又購買了 25,816 股。國際資產投資管理公司在第二季度購買了 MIRA Pharmaceuticals 的新頭寸，價值約 42,000 美元。Creative Planning 在第二季度購買了 MIRA Pharmaceuticals 的新頭寸，價值約 27,000 美元。最後，XTX Topco Ltd 在第二季度購買了 MIRA Pharmaceuticals 的新股份，價值約 26,000 美元。對沖基金和其他機構投資者持有該公司 35.16% 的股票。</p>
<h2>MIRA Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>MIRA Pharmaceuticals, Inc.是一家處於臨牀前階段的製藥開發公司，擁有兩個神經科學項目，針對一系列神經和精神疾病。該公司擁有 Ketamir-2 的美國、加拿大和墨西哥獨佔權，這是一種正在研究的口服氯胺酮類似物，旨在為正在與難治性抑鬱症、伴有自殺意念的重度抑鬱症和創傷後應激障礙作鬥爭的個人提供超快速的抗抑鬱效果。</p>
<h2>特色文章</h2>
<ul>
<li>我們更看好的五隻股票超過 MIRA Pharmaceuticals</li>
<li>工業產品股票投資</li>
<li>在上漲 35% 後，分析師關注銅巨頭 Freeport 的更多上漲空間</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>為什麼 SpaceX 的 IPO 可能成為 GOOGL 股票的主要催化劑</li>
<li>FTSE 100 指數是什麼？</li>
<li>Upwork 能否維持其復甦？看漲和看跌的理由</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 MIRA Pharmaceuticals 嗎？</h2>
<p>在你考慮 MIRA Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MIRA Pharmaceuticals 並不在名單上。</p>
<p>雖然 MIRA Pharmaceuticals 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MIRA

<p>MIRA Pharmaceuticals (NASDAQ:MIRA) 的股票在交易中上漲了 2.1%，最高達到 1.55 美元，最後交易價格為 1.48 美元。交易量比平均水平增加了 125%。儘管股價上漲，分析師已將該股票評級下調至 “賣出”。公司報告了季度虧損，未能達到預期。機構投資者已調整其持倉，持有該股票的比例為 35.16%。MIRA 專注於開發神經系統疾病的治療方案</p>

<p>MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) rose 2.1% during trading on Wednesday . The company traded as high as $1.55 and last traded at $1.48. Approximately 418,018 shares changed hands during trading, an increase of 125% from the average daily volume of 185,498 shares. The stock had previously closed at $1.45.</p>
<div class="lb-trans"><p>MIRA Pharmaceuticals, Inc.（納斯達克代碼：MIRA - 獲取免費報告）在週三的交易中上漲了 2.1%。該公司的股價最高達到 1.55 美元，最後交易價格為 1.48 美元。在交易中大約有 418,018 股易手，比平均每日交易量 185,498 股增加了 125%。該股票之前的收盤價為 1.45 美元。</p>
</div><p>Get <strong>MIRA Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>MIRA Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of brokerages recently weighed in on MIRA. Wall Street Zen downgraded shares of MIRA Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, November 22nd. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of MIRA Pharmaceuticals in a research note on Wednesday, December 10th. One analyst has rated the stock with a Sell rating, According to MarketBeat, MIRA Pharmaceuticals has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>多家券商最近對 MIRA 進行了評估。華爾街 Zen 在 11 月 22 日的報告中將 MIRA Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。Weiss Ratings 在 12 月 10 日的研究報告中重申了對 MIRA Pharmaceuticals 的 “賣出（d-）” 評級。根據 MarketBeat 的數據顯示，一位分析師對該股票給予了賣出評級，MIRA Pharmaceuticals 的共識評級為 “賣出”。</p>
</div><p><strong>Check Out Our Latest Report on MIRA Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 MIRA Pharmaceuticals 的最新報告</strong></p>
</div><h2>MIRA Pharmaceuticals Stock Up 2.1%</h2>
<div class="lb-trans"><h2>MIRA Pharmaceuticals 股票上漲 2.1%</h2>
</div><p>The stock has a market cap of $61.98 million, a P/E ratio of -0.97 and a beta of 1.79. The business's 50-day simple moving average is $1.47 and its two-hundred day simple moving average is $1.42.</p>
<div class="lb-trans"><p>該股票的市值為 6198 萬美元，市盈率為-0.97，貝塔值為 1.79。該公司的 50 日簡單移動平均線為 1.47 美元，200 日簡單移動平均線為 1.42 美元。</p>
</div><p>MIRA Pharmaceuticals (NASDAQ:MIRA - Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($1.07). Analysts anticipate that MIRA Pharmaceuticals, Inc. will post -0.6 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>MIRA Pharmaceuticals（納斯達克代碼：MIRA - 獲取免費報告）最近在 11 月 13 日發佈了季度財報。該公司報告每股收益（EPS）為-1.18 美元，低於共識預期的-0.11 美元，差距為-1.07 美元。分析師預計 MIRA Pharmaceuticals, Inc.在當前財政年度的每股收益將為-0.6 美元。</p>
</div><h2>Institutional Investors Weigh In On MIRA Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 MIRA Pharmaceuticals 的看法</h2>
</div><p>Several institutional investors have recently made changes to their positions in MIRA. First American Bank grew its position in shares of MIRA Pharmaceuticals by 150.0% in the third quarter. First American Bank now owns 50,000 shares of the company's stock valued at $68,000 after purchasing an additional 30,000 shares in the last quarter. Two Sigma Investments LP boosted its stake in MIRA Pharmaceuticals by 129.8% in the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company's stock worth $62,000 after purchasing an additional 25,816 shares during the period. International Assets Investment Management LLC purchased a new position in MIRA Pharmaceuticals during the 2nd quarter valued at about $42,000. Creative Planning purchased a new position in MIRA Pharmaceuticals during the 2nd quarter valued at about $27,000. Finally, XTX Topco Ltd bought a new stake in shares of MIRA Pharmaceuticals during the second quarter valued at about $26,000. Hedge funds and other institutional investors own 35.16% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者最近對 MIRA 的持倉進行了調整。第一美洲銀行在第三季度將其在 MIRA Pharmaceuticals 的持倉增加了 150.0%。第一美洲銀行現在擁有 50,000 股該公司的股票，價值 68,000 美元，此前在上個季度又購買了 30,000 股。Two Sigma Investments LP 在第三季度將其在 MIRA Pharmaceuticals 的股份增加了 129.8%。Two Sigma Investments LP 現在擁有 45,703 股該公司的股票，價值 62,000 美元，此前在此期間又購買了 25,816 股。國際資產投資管理公司在第二季度購買了 MIRA Pharmaceuticals 的新頭寸，價值約 42,000 美元。Creative Planning 在第二季度購買了 MIRA Pharmaceuticals 的新頭寸，價值約 27,000 美元。最後，XTX Topco Ltd 在第二季度購買了 MIRA Pharmaceuticals 的新股份，價值約 26,000 美元。對沖基金和其他機構投資者持有該公司 35.16% 的股票。</p>
</div><h2>MIRA Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>MIRA Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.</p>
<div class="lb-trans"><p>MIRA Pharmaceuticals, Inc.是一家處於臨牀前階段的製藥開發公司，擁有兩個神經科學項目，針對一系列神經和精神疾病。該公司擁有 Ketamir-2 的美國、加拿大和墨西哥獨佔權，這是一種正在研究的口服氯胺酮類似物，旨在為正在與難治性抑鬱症、伴有自殺意念的重度抑鬱症和創傷後應激障礙作鬥爭的個人提供超快速的抗抑鬱效果。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than MIRA Pharmaceuticals</li>
<li>Industrial Products Stocks Investing</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
<li>What is the FTSE 100 index?</li>
<li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 MIRA Pharmaceuticals</li>
<li>工業產品股票投資</li>
<li>在上漲 35% 後，分析師關注銅巨頭 Freeport 的更多上漲空間</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>為什麼 SpaceX 的 IPO 可能成為 GOOGL 股票的主要催化劑</li>
<li>FTSE 100 指數是什麼？</li>
<li>Upwork 能否維持其復甦？看漲和看跌的理由</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MIRA Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 MIRA Pharmaceuticals 嗎？</h2>
</div><p>Before you consider MIRA Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 MIRA Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MIRA Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MIRA Pharmaceuticals 並不在名單上。</p>
</div><p>While MIRA Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MIRA Pharmaceuticals 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

MIRA Pharmaceuticals（NASDAQ:MIRA）股價上漲 2.1% - 事情經過如下